Headquartered in New York, Colgate-Palmolive Company (CL) is a premier manufacturer and seller of consumer products in the United States and internationally. With a market cap of $76.2 billion, the company operates through two segments: Oral, Personal and Home Care; and Pet Nutrition and offers products under famous brands including Colgate, Palmolive, Darlie, elmex, hello, meridol, and Sorriso.

The consumer goods giant is expected to report its Q2 earnings on Friday, Aug. 1, before the market opens. Ahead of the event, analysts expect CL to report an EPS of $0.88 per share, down 3.3% from $0.91 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in all of the past four quarters, which is admirable.

For fiscal 2025, analysts expect CL to report an adjusted EPS of $3.65, up 1.4% from $3.60 in fiscal 2024. In fiscal 2026, its adjusted EPS is expected to grow 7.4% year-over-year to $3.92.

Over the past year, CL shares have declined 3.8%, underperforming the S&P 500 Index’s ($SPX) 11.9% rally and the Consumer Staples Select Sector SPDR Fund’s (XLP) 6.1% return over the same time frame.

On Apr. 25, Colgate-Palmolive shares edged up 1.3% following the release of its Q1 earnings report. While net sales declined 3% year-over-year to $4.9 billion, they still came in 1% above consensus estimates. Despite sluggish category growth in several markets, the company saw an improvement in organic sales, highlighting the resilience of its brand portfolio and the successful execution of its strategic initiatives. Adjusted EPS rose 5.8% year-over-year to $0.91, surpassing Wall Street expectations.

The consensus opinion on CL stock is moderately optimistic, with an overall “Moderate Buy” rating. Out of the 20 analysts covering the stock, 10 recommend a “Strong Buy,” two suggest a “Moderate Buy,” six suggest a “Hold” rating, and the remaining two suggest a “Strong Sell” rating. Its mean price target of $98.50 indicates a 5.5% upside potential from current price levels.